Kyowa Kirin Pharmaceutical Research, Inc.
212 Carnegie Center Drive
73 articles about Kyowa Kirin Pharmaceutical Research, Inc.
MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies;
Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program
MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401
MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing
BioSpace Movers & Shakers, April 10
4/10/2020Biopharma companies strengthen their leadership teams and boards with this week's Movers & Shakers.
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes
First and only Adenosine A2A receptor antagonist for use in Parkinson’s disease in the U.S.
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced plans to submit a supplemental Biologics License Application to the U.S. Food and Drug Administration for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease
First and only Adenosine A2A receptor antagonist for use in Parkinson’s Disease in the U.S.
Nourianz (istradefylline) was given the thumbs-up as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “OFF” episodes.
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
FDA Approves Eight Novel Drugs in August
8/31/2018The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo injection.
ASCO 2018: Results Keep Rolling In
6/4/2018There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
Ultragenyx And Kyowa Hakko Kirin Announce FDA Acceptance And Priority Review Designation Of Burosumab’s Biologics License Application
Syndax Announces Dosing Of First Patient In Pivotal Trial Of Entinostat For The Treatment Of Advanced Or Recurrent Breast Cancer In Japan By Partner Kyowa Hakko Kirin
Kyowa Hakko Kirin Joins Certara Corporation’s Simcyp Consortium
Ultragenyx And Kyowa Hakko Kirin Announce Submission Of Burosumab’s Biologics License Application In The U.S.
Ultragenyx, Kyowa Hakko Kirin And Kyowa Kirin International Announce Positive 24-Week Data From Adult Phase II Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com
Kyowa Hakko Kirin And Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S.